Company: TVRD
Filing Date: 2025-05-27
Form Type: 8-K
Source: 0001104659-25-052733
Chunk: 0

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-27
Form: 8-K
Item: Item 7.01
Chunk 0
---
Item 7.01. Regulation FD Disclosure.

On May 27, 2025, Tvardi Therapeutics,
Inc. (the “ Company”) issued a press release entitled “ Tvardi Therapeutics Announces Completion of Enrollment in Phase
2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis.” A copy of the press release is furnished as Exhibit 99.1 to this
Current Report on Form 8-K.

The information in this Item
7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities
of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange
Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.